From bench to bedside: reversing established antibody responses and desensitization

Area of Science:

• Transplant immunology
• Immunotherapy
• Clinical translation

Background:

• Donor-specific antibodies (DSA) are critical in transplant rejection, causing hyperacute, early, and chronic antibody-mediated rejection (AMR).
• Current immunosuppression is insufficient for pre-existing DSA or established antibody responses, necessitating novel therapeutic strategies.
• Translating basic research into effective therapies for transplant rejection remains a key goal.

Purpose of the Study:

• To review the development of a novel bench-to-bedside therapeutic approach for managing donor-specific antibodies (DSA).
• To evaluate the efficacy of transient proteasome inhibition combined with co-stimulation blockade in reversing established DSA responses and preventing antibody-secreting cells (ASCs) generation.

Main Methods:

• The review focuses on a treatment regimen combining transient proteasome inhibition for plasma cell depletion with maintenance co-stimulation blockade (CTLA-4Ig/belatacept) to inhibit new ASCs.
• This approach was rationally designed and validated in preclinical mouse models.

Main Results:

• The described treatment regimen successfully reversed established DSA responses in preclinical models.
• Clinical translation demonstrated reversal of active antibody-mediated rejection (AMR) and desensitization of highly sensitized patients awaiting transplantation.

Conclusions:

• This combined therapeutic strategy represents a significant advancement in managing DSA-mediated transplant rejection.
• The bench-to-bedside translation of proteasome inhibition and co-stimulation blockade offers a promising new avenue for improving transplant outcomes and patient eligibility.